Humana's Star Ratings Surge: Implications for Medicare Advantage 2027

Shares of Humana surged by 15% following analyst recognition of the company as a primary beneficiary from the forthcoming star ratings for Medicare Advantage plans in 2027.

This optimistic outlook signals important implications for insurance professionals, particularly regarding the Medicare Advantage landscape. Humana projects that an impressive 95% of its Medicare Advantage members will be enrolled in plans with at least four-star ratings by 2027. This marks a drastic improvement from a mere 20% in 2026 and shatters J.P. Morgan's estimates, which predicted only 60% to 70% of members in similarly rated plans. The enhancement in star ratings unlocks opportunities for substantial government bonus payments, a financial boon that insurers covet.

Impact on the Competitive Landscape

The improvement in Humana's position puts it ahead of key competitors. According to J.P. Morgan, UnitedHealth is anticipated to see a reduction in its members enrolled in Medicare Advantage plans rated four stars or higher, from 81% down to about 67%. Similarly, CVS Health is expected to see a decline from 84% to around 70%. These shifts illustrate the potential disruptions in market share and strategic positioning within the Medicare Advantage marketplace.

Challenges and Future Prospects

Humana's recent successes stand in stark contrast to its earlier difficulties following a significant downturn in star ratings for 2025. This downgrade jeopardized future bonus payments and posed a challenge for profit goals. However, advancements in drug-plan quality, health-plan quality, and readmissions have turned the tide. Elizabeth Anderson from Evercore ISI forecasts these improvements might yield around $4.8 billion in bonus payments by 2028.

Humana's Strategic Focus

For Humana, capitalizing on these ratings will not only depend on star metrics but also on reinvestments in member benefits and working closely with healthcare providers. The U.S. health department's report that roughly 71% of Medicare Advantage prescription drug plan members will be in four-star or higher-rated plans by 2027 reinforces the critical importance of high-quality service and strategic compliance for continued success.